Using a new approach to improve treatment for acute myeloid leukemia
Creating a transient metabolic catastrophe for AML therapy
This study is exploring a new way to help people with acute myeloid leukemia (AML) by using a special combination of treatments that could make the cancer cells easier to kill, and it's designed for patients looking for better options to fight their disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11100030 on NIH RePORTER |
What this research studies
This research investigates a novel treatment strategy for acute myeloid leukemia (AML) by combining a small molecule that activates a specific cellular pathway with proteasome inhibitors. The goal is to create conditions that make AML cells more susceptible to treatment by inducing stress and damaging their mitochondria. By understanding how these treatments work together, the researchers aim to enhance the effectiveness of existing therapies and overcome resistance in AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia who have not responded well to standard therapies.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with acute myeloid leukemia.
How similar studies have performed: Other research has shown promising results using similar approaches to enhance the effectiveness of cancer therapies, indicating potential for success in this area.
Where this research is happening
Cleveland, United States
- Case Western Reserve University — Cleveland, United States (Active)
Researchers
- Principal investigator: Tirosh, Boaz — Case Western Reserve University
- Study coordinator: Tirosh, Boaz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.